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Abstract
Down syndrome (DS), trisomy of chromosome 21, is the most common genetic form of 
intellectual disability. The neuropathology of DS involves multiple molecular mechanisms, similar 
to AD, including the deposition of beta-amyloid (Aβ) into senile plaques and tau 
hyperphosphorylating in neurofibrillary tangles. Interestingly, many genes encoded by 
chromosome 21, in addition to being primarily linked to amyloid-beta peptide (Aβ) pathology, are 
responsible for increased oxidative stress (OS) conditions that also result as a consequence of 
reduced antioxidant system efficiency. However, redox homeostasis is disturbed by overproduction 
of Aβ, which accumulates into plaques across the lifespan in DS as well as in AD, thus generating 
a vicious cycle that amplifies OS-induced intracellular changes.
The present review describes the current literature that demonstrates the accumulation of oxidative 
damage in DS with a focus on the lipid peroxidation by-product, 4-hydroxy-2-nonenal (HNE). 
HNE reacts with proteins and can irreversibly impair their functions. We suggest that among 
different post-translational modifications, HNE-adducts on proteins accumulate in DS brain and 
play a crucial role in causing the impairment of glucose metabolism, neuronal trafficking, protein 
quality control and antioxidant response. We hypothesize that dysfunction of these specific 
pathways contribute to accelerated neurodegeneration associated with AD neuropathology.
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1. Down Syndrome neuropathology
Down syndrome (DS) is a genetic disorder that results from the triplication of the entire 
portion or part of chromosome 21 (Chr21) and is considered the major genetic cause of 
intellectual disability. DS occurs in 1 every 800/1000 live births and presents several 
pathological phenotypes such as craniofacial abnormalities, small brain size, accelerated 
aging, cardiac defects and cognitive decline. The “gene dosage hypothesis” states that the 
increased dosage of Chr21 genes is the direct cause of the phenotypical alterations of DS 
[1-3]. However, the presence of trisomic genes also affects the expression of disomic genes, 
which, in turn, may gain aberrant expression and contribute to some clinical manifestations 
[3]. In this deregulated scenario, the effects caused by some dosage-sensitive genes are 
amplified and result in heterogeneous phenotypic traits according to the “number and dose” 
of genes involved [4]. Life expectancy in the DS population is shorter compared with non-
DS individuals, but improvements in medical care and drug treatments have significantly 
contributed to ameliorate the quality of life of people with DS [5, 6]. Numerous 
developmental defects are associated with DS [7, 8], with brain development and intellectual 
disabilities being the most striking features of trisomy 21 [9, 10], and language, learning and 
memory may also be affected [11]. Unravelling the molecular mechanisms related to 
accelerated aging and neurodegeneration is one of the major challenges of research both for 
DS and AD.
Several studies support the link between the DS phenotype and an increased risk of 
development of AD [12]. The incidence of dementia among DS patients is 10% in the age 
range 35–50, 55% in the age range 50–60, and becomes 75% above the age of 60 years, but 
AD neuropathology is present in virtually all adults with DS older than 40 years [13]. 
However, there is a subset of aged DS persons who do not develop clinical signs of dementia 
at any age [14]. Neuropathological features of AD are the deposition of senile plaques (SPs) 
and neurofibrillary tangles (NFTs) together with cholinergic and serotonergic reduction [15, 
16]. However, although plaques have been detected in young DS autopsy samples, some as 
young as in the fetus, it is only in late middle age that people with DS develop AD 
pathology.
2. Increased oxidative stress in DS contributes to development of 
Alzheimer Disease neuropathology
Several studies demonstrate that oxidative stress (OS) is involved in the development of 
multiple DS phenotypes (reviewed in [17]). OS represents an imbalance between the 
production of ROS and the efficiency of antioxidant systems - antioxidant compounds and 
antioxidant enzymes - to detoxify the reactive intermediates or to repair the oxidative 
damage [18, 19]. High levels of OS-induced by-products have been detected in brain tissue 
from DS [19, 20]. Intriguingly, the causes of increased OS in DS may be searched by 
mapping Chr21, where a number of genes, directly or indirectly, promote free radical 
production and alter redox homeostasis of neuronal cells. Among candidate genes, the 
overexpression of SOD1 and APP are considered to be the leading causes of OS (Figure 1).
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SOD-1 is one of the major enzymes involved in the antioxidant defense and catalyzes the 
dismutation of O2•− to molecular oxygen and H2O2, which in turn is metabolized by catalase 
(CAT) and by glutathione peroxidase (GPX) to water [21]. However, considering that brain 
levels of CAT and GPX are generally lower in the brain compared with other tissues, 
triplication of SOD-1 in DS brain results in an imbalance in the ratio of SOD-1 to CAT and 
GPX, thus leading to the accumulation of H2O2 [22]. Interestingly, this condition - altered 
SOD-1/GPX activity ratio - is not restricted to the brain but occurs also in all DS tissues 
[23]. The expression levels of SOD-1 were found to be around 50% higher in different DS 
cells and tissues, such as erythrocytes, lymphocytes and fibroblasts compared with euploid 
control cells. SOD-1, SOD-1/GPX or the SOD-1/(GPX + CAT) activity ratios were 
increased in erythrocytes from people with DS, either children or adults. Findings from Shin 
and colleagues demonstrate that transgenic mice overexpressing wild-type human SOD1 
(Tg-SOD1) displayed mitochondrial swelling, vacuolization, learning and memory deficits 
[24]. Similarly, Busciglio et al. [25] showed that DS neurons have higher ROS levels that are 
also associated with elevated markers of LPO. Nevertheless, proteomics results from 
Gulesserian et al. [26] suggest that increased OS conditions in fetal DS tissues are not 
exclusively caused by SOD-1 triplication but may be significantly associated with reduced 
activity of antioxidant enzymes, such as glutathione transferases and thioredoxin 
peroxidases.
Several studies also suggest that increased ROS production in DS could result as a 
consequence of amyloid beta-peptide (Aβ) overproduction [27-29], due to the 
overexpression of the amyloid precursor protein (APP) gene, encoded on Chr21. Several 
studies from the Butterfield group and others [30-32] indicate that Aβ induces OS. OS 
occurs within the bilayer, where Aβ(1-42) inserts as oligomers and serves as a source of 
ROS and initiates LPO (Figure 1) [30]. Deposition of senile plaques is observed in post-
mortem brain from DS individuals [33] and levels of both Aβ(1-42) and Aβ(1-40) in plasma 
are higher in DS compared with non-DS controls [34].
Interestingly, studies from Anandatheerthavarada et al. [35] also suggest that full length APP 
may be neurotoxic, primarily at the mitochondrial level. These authors suggest that 
increased APP expression causes a progressive accumulation of transmembrane-arrested 
APP that in turn disturbs mitochondrial integrity, which ultimately results in impairment of 
energy metabolism. Other studies support this evidence by showing that mice 
overexpressing wild type human APP develop neuropathology similar to AD, but lack 
significant plaque deposition in the hippocampus [36]. These findings led to the hypothesis 
that overexpression of APP may promote mitochondrial dysfunction in DS independent of 
aberrant Aβ deposition.
Another Chr21 gene that could play a role in exacerbating OS is the enzyme carbonyl 
reductase (CBR). Carbonyls are toxic metabolic intermediates that are mainly detoxified by 
aldehyde dehydrogenase or reduced by CBR and/or alcohol dehydrogenase to their 
corresponding alcohols. The finding that expression levels of these enzymes are increased in 
different brain regions of both DS and AD patients suggests they may be a protective 
response toward increased carbonyl production, i.e., increased oxidative damage [37]. 
However, CBR itself can be oxidatively modified as observed in the brains of people with 
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mild cognitive impairment (MCI), and once irreversibly damaged it may lose functionality 
[38].
Another interesting aspect of trisomy 21 is the role of cystathionine beta synthase (CBS) that 
may possibly link OS to metabolic defects. CBS is the first enzyme involved in the trans-
sulfuration pathway and catalyzes the condensation of homocysteine with serine to form 
cystathionine [39]. CBS catalyzes the condensation of serine and homocysteine to form 
cystathionine and water. CBS plays a critical role in linking the folate cycle and the 
methionine cycle and in regulating homocysteine levels [40]. In addition, CBS can also use 
cysteine alone or together with homocysteine to generate hydrogen sulfide, which has been 
shown to exert important neuromodulatory activities in the brain [41]. CBS protein levels 
and enzyme activity are increased in persons with DS [42]. This increase of CBS activity 
can lead to lower homocysteine levels, which in turn disturb the balance of one-carbon 
metabolism and lead to elevated, possibly toxic, levels of hydrogen sulfide. Taken together, 
these metabolic alterations might contribute to the cognitive decline observed in DS with age 
[43]. In line with this hypothesis, CBS is currently considered a risk factor for AD [44].
Additional trisomic genes that may be indirectly involved in the increased susceptibility of 
different cell types in DS to accumulate oxidative damage are those encoding for S100β and 
Ets-2.
S100β, an astroglial-derived Ca2+-binding protein, acts as a neurotrophic factor on neurons 
and glial cells. S100β interacts with a variety of intracellular targets, such as microtubules, 
enzymes of the glycolytic pathway and with the tumor suppressor p53. S100β also regulates 
calcium homeostasis, protein phosphorylation and degradation. In the brain, S100β is 
actively secreted from astrocytes in the extracellular medium [45] and has been shown to 
modulate the activity of neurons, microglia, astrocytes, monocytes, and endothelial cells. On 
neurons, S100β triggers trophic or toxic effects, depending on its concentration. S100β 
expression levels are increased in both DS and AD astrocytes in association with neuritic 
plaques [46, 47]. In addition, chronic overexpression of S100β contributes to increased 
neuronal and neuritic βAPP expression with consequent accelerated amyloid deposition, as 
well as abnormal growth of neurites in β-amyloid plaques, similar to observations in middle-
aged DS patients [46].
Ets-2 is a member of the Ets family of transcription factors that has important functions in 
cancer, bone development and immune responses. Experimental evidence shows that Ets-2 is 
upregulated by OS and it is involved in cell differentiation, maturation and signaling [48]. 
The overexpression of Ets-2 could play a role in the increased susceptibility of DS cells to 
undergo apoptosis given common pathophysiological features shared between Ets-2 
overexpressing transgenic mice and individuals with DS [49]. Intriguingly, although Ets-2 
overexpression is involved in neuronal apoptotic cell death it is conceivable that it may also 
play a role in the reduced incidence of solid tumors in people with DS [50].
Taken together, this “genetic fingerprint” suggests that DS individuals are exposed to 
chronic doses of free radicals from embryonic development until adult life as discussed 
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below. Paradoxically, this may also result in activation of compensatory mechanisms as a 
consequence of increased OS burden [51].
3. Lipid peroxidation and neurodegeneration: HNE and application of redox 
proteomics to Down Syndrome brain
The central nervous system (CNS) is one of the major targets of lipid peroxidation (LPO) 
chain reactions. This susceptibility of the brain to LPO is because this organ consumes about 
30% of inspired oxygen, contains high levels of polyunsaturated fatty acids (PUFAs), as 
phospholipids, and a significant concentration of redox transition metal ions. PUFAs, in the 
lipid bilayer of the plasma membrane, are the first site for H-atom removal, specifically at 
the level of a repeating =CH-CH(2)-CH= unit, that in addition to conferring an extremely 
flexible structure, is chemically vulnerable. Indeed, it has been shown that the substitution of 
deuterium for hydrogen at oxidation-prone bisallylic sites of these essential fatty acids 
provides neuroprotection in a mouse model of OS and neurodegeneration [52].
The first reaction in LPO cascade is the abstraction of an H-atom from the conjugate double 
bond system of the fatty acid acyl chain, which in turn activates a cascade of radical 
reactions. As a consequence, a variety of free radical species (ROS) are released. Altogether, 
ROS are highly unstable and easily react with all macromolecules such as proteins, nucleic 
acid and lipids. All these events are further exacerbated by the relative inability of neuronal 
cell to neutralize free radicals as the expression of antioxidant enzymes is generally lower in 
the brain compared with other tissues [53].
Oxidative breakdown of biological phospholipids occurs in most cellular membranes 
including mitochondria, microsomes, peroxisomes and plasma membrane. Free radical 
attack to PUFAs produces a wide variety of oxidation products, among which lipid 
hydroperoxides (LOOH), many different aldehydes, which can be formed as secondary 
products during LPO, malondialdehyde (MDA), propanal, hexanal, acrolein and 4-
hydroxynonenal (4-HNE) [54, 55]. MDA is the most mutagenic [56] whereas 4-HNE is the 
most toxic [55]. In addition to these by-products, lipid hydroperoxyl radicals undergo 
endocyclization to produce fatty acid esters; two classes of these cyclized fatty acids are 
ispoprostanes and neuroprostanes [57].
Within the bilayer lipid soluble vitamins, glutathione, glutathione-S-transferases are the 
major scavengers towards lipid oxidants including HNE and provide the first line of defense. 
In addition, albumin and apolipoproteins in plasma can bind and detoxify HNE. However, 
cells do not possess a specific repair system against LPO as it occurs for repairing DNA 
damage and this may explain why moderate levels of LPO could have physiological 
significance for cell signaling and membrane remodeling [58].
Peroxidation of membrane lipids results in increased membrane rigidity and impairment of 
multiple membrane-associated functions including activity of membrane-bound enzymes 
(e.g., sodium pump), disturbance of membrane receptors and altered permeability to 
molecules [55]. In addition to damage to phospholipids, radicals also can directly attack 
membrane proteins and induce lipid-protein and protein-protein crosslinking, all of which 
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contribute to disturb membrane integrity [59]. Taken together, disturbance of all the above-
mentioned functions displayed by PUFAs and its metabolites and the irreversible 
modifications of proteins with LPO by-products, affect neuronal homeostasis thus 
contributing to brain dysfunction.
The role of LPO in the pathogenesis and progression of neurodegenerative disorders has 
been confirmed by different studies [60, 61]. These findings showed the elevation of markers 
of LPO in brain tissue and body fluids in several neurodegenerative diseases, including AD, 
Parkinson disease (PD), amyotrophic lateral sclerosis (ALS), Huntington disease (HD) and 
DS [60, 62]. In particular, this review focuses on the role of LPO in the brains of people with 
DS and its role in the development of AD.
HNE is a key component of OS because it is produced in relatively large amounts, and it is a 
reactive aldehyde that acts as “second messenger” of free radicals [63]. Thus 4-HNE can act 
both as signaling molecule and as cytotoxic product of LPO causing chronic biological 
consequences, in particular by causing covalent modification of all macromolecules (Figure 
1).
HNE, an α,β unsaturated electrophilic compound, is an amphiphilic compound, that can 
interact with both water-soluble and lipophilic environments. However, it has stronger 
hydrophobic nature and it is mostly associated with the membrane structures where it is 
formed, but it has the ability to diffuse in other cellular compartments and therefore interacts 
with different substrates [53]. HNE is a highly reactive compound due to the presence of 
three functional groups responsible of its electrophilic properties [64]. The presence of a 
conjugated system of a C=C double bond and a CO carbonyl group provide a partial positive 
charge to carbon 3, that is further increased by the inductive effect of the hydroxy group at 
carbon 4. For these reasons the nucleophilic attack, for example, by thiol or amino groups, 
occurs primarily at carbon 3 and second at the carbonyl carbon 1. Proteins are particularly 
susceptible to HNE-induced modification and HNE forms Michael adducts with three 
different side chains amino acids, namely Cys, His, and Lys, either with thiol (-SH) and 
amino (-NH2) groups of these amino acids [65]. Cys residues have the highest reactivity, 
with Cys>His>Lys. As it occurs for many protein modifications, the degree of reactivity 
depends on the tertiary structure of the protein - accessibility - and therefore reactivity, of 
amino acid residues towards exogenous chemicals. 4-HNE adducts play a critical role in 
multiple cellular processes and can participate in secondary deleterious reactions (e.g., 
crosslinking) by promoting intramolecular or intermolecular protein/DNA crosslinking that 
may induce profound alteration in the biochemical properties of biomolecules, which may 
facilitate development of various pathological states.
Several proteins undergo HNE modification such as plasma membrane ion and nutrient 
transporters; receptors for growth factors and neurotransmitters; mitochondrial electron 
transport chain proteins; protein chaperones; proteasomal proteins; and cytoskeletal proteins 
[65, 66]. The effects of this modification are wide and with diverse severity but having, as a 
whole, a significant effect on protein functionality.
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Moreover, the function of any given protein is finely regulated by post-translational 
modifications (PTMs) such as phosphorylation, acetylation, methylation, glutathionylation, 
ubiquitinylation among others. These modifications are generally reversible and are 
fundamental to regulate normal cellular functions. However, a different set of PTMs, which 
often lead to irreversible protein modifications, may also occur and give rise to dangerous 
effects. Among these types of potentially “toxic” changes, oxidative modification, such the 
covalent bonding to HNE, have been extensively investigated mostly in neurodegenerative 
diseases, conditions in which increased OS is a constant treat for protein homeostasis. 
Indeed, oxidation of a protein results in its impaired function and mostly the accumulation of 
oxidized proteins is a characteristic hallmark of degenerating neurons in AD and other 
neurodegenerative diseases [67].
4. HNE-modified proteins contribute to neurodegeneration in Down 
Syndrome
There is considerable literature supporting a major role for OS in DS clinical phenotypes. 
Direct evidence for a pro-oxidant state in people with DS includes those studies 
demonstrating significant increases in oxidative DNA damage (urinary 8-OHdG), LPO, and 
isoprostane 8,12-iso-iPF2alpha-VI in DS patients [27, 37, 71-73].
Relevant to the focus of this review, an increase of markers of LPO (TBARS) was found in 
the urine of young DS patients (about 5 years old in average) with respect to their age 
matched controls [71]. Similarly, Praticò et al. found elevated levels of the isoprostane 8,12-
iso-iPF2alpha-VI – a specific marker of LPO – in urine samples from young DS subjects 
(ranging from 1 to 15 years old) [27].
The pro-oxidant state in DS may contribute to our understanding of the mechanisms 
underlying several DS phenotypes. In particular, age-dependent measures of OS biomarkers 
in DS could provide insights into their contribution to accelerated ageing and to the other 
age associated, redox-related pathologies. An age-dependent analysis of redox parameters 
evaluated in plasma samples from DS subjects (1-57 years old) suggests that changes in 
redox status is strictly linked to age [74]. Indeed, Pallardo and colleagues showed a 
significant increase in 8-OHdG levels in DS patients up to 30 years old. Further, the 
GSSG:GSH ratio was significantly higher in young DS patients (<15 years), while it is 
reduced in DS patients aged >15 years. Plasma levels of markers of protein oxidation 
including glyoxal (Glx) and methylglyoxal (MGlx) provided opposite results. Glx levels 
were significantly higher in young DS patients, whereas no significant difference was 
detected in DS patients aged >15 years. Suprisingly, MGlx was significantly lower in young 
DS subjects. Levels of antioxidants including ascorbic acid and vitamin E were also 
evaluated, showing that plasma concentrations of ascorbic acid are increased in young (<15 
years) DS patients, but not in older patients, while the levels of vitamin E did not differ from 
control neither in young or older DS subjects [74]. These results, although in agreement with 
previous studies of an early pro-oxidant state occurring in DS [27, 71], also provide 
additional contributors accounting for a multi-faceted pro-oxidant state in DS patients, 
depending on age. The contribution of these age-associated changes may impact a number of 
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phenotypic features of DS including accelerated ageing, cancer propensity in childhood, 
neurological and cognitive impairment and immunodeficiency.
Increased LPO levels evaluated as MDA production in plasma from DS patients (from new 
born to 29 years old) were also reported [75]. Interestingly, a pilot study evaluating plasma 
levels of HNE in DS patients (2-16 years old) also revealed a marked increase of HNE in DS 
with respect to their age-matched controls, thus reinforcing the hypothesis of a pro-oxidant 
state occurring early in DS [76].
The role of GSH in LPO and HNE formation also appears to be important. The increased 
GSSG/GSH ratio in young DS patients (<15 years) is in agreement with observed elevation 
of LPO. Nevertheless, the GSSG/GSH ratio is reduced in plasma sample collected from 
older DS patients [74] possibly suggesting an activation of the antioxidant defense in 
response prolonged HNE exposure. However, this compensatory mechanism, that promotes 
synthesis of GSH through HNE-mediated induction of glutamate cysteine ligase (GCL) [77], 
is not coupled with decrease markers of LPO in DS older patients [9].
In addition, Perluigi et al. also describe changes occurring in amniotic fluid (AF), which are 
a more reliable index of the physiological condition of the fetus. The biochemical 
composition of AF, routinely used for prenatal diagnosis, is modified throughout pregnancy 
and its protein profile reflects both physiological and pathological changes affecting the 
fetus and the mother [78]. AF from DS pregnancies is characterized by increased levels of 
HNE, indicating that the LPO pathways were enhanced even at the fetal stage in DS [79]. 
Furthermore, in good agreement with previous studies an increase of GSSG/GSH ratio was 
found already at the level of AF [79], thus strongly support for a very early occurrence of a 
pro-oxidant state in DS. Indeed, it is important to note that, in contrast to adult brain, fetal 
DS neurons do not overexpress SOD-1, and therefore the impaired oxidative status may 
occur primarily as a consequence of the low levels of reducing agents and enzymes involved 
in the removal of ROS [80].
Based on the above results it appears that an increase of OS occurs early in the lifespan of 
people with DS. Whether these peripheral changes are paralleled in the brain and thus might 
be associated with intellectual disability has yet to be evaluated.
Studies performed in Ts65Dn mice (the most used animal model for the study of DS 
neurodegeneration) support the accumulation of oxidative/nitrosative damage in the brain. 
Although Ts65Dn mice do not present all the features associated with DS (such as 
congenital heart defects), they display many DS-like features, including significant 
performance deficits in specific behavioral tasks, motor dysfunction, craniofacial 
dysmorphogenesis, and age-related loss of cholinergic markers in the basal forebrain [81].
Increased LPO products such as 8,12-iso-iPF2alpha-VI are observed both in the cortex and 
hippocampus of very young mice (2 months) [82], whereas increased HNE levels are found 
in the hippocampus of both 6- and 12-months olds mice [83]. HNE levels in very young 
mice have yet to be reported, but the increase of other LPO products could suggest an 
increase of HNE as well.
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However, results collected in young mice are consistent with data on human AF and with the 
hypothesis that OS is a very early event occurring within fetal stage. Indeed, administration 
of α-tocopherol to pregnant Ts65Dn females from the day of conception throughout the 
pregnancy prevented the increase in LPO [83]. Furthermore, Gulesserian et al. found a 
significant reduction in levels of glutathione synthetase, glutathione-S-transferase and 
thioredoxin peroxidase-I and -II in DS fetal brain compared with controls, thus supporting 
an early impairment of GSH pathway which may contribute to the observed increase in LPO 
[26].
In addition, as proposed by Tramutola et al. the accumulation of HNE and HNE-bound 
proteins with age, could be dependent on the coexistent increase in OS together with the 
reduced turnover of damaged proteins. Autophagy, necessary for protein turnover, is 
inversely dependent on mTOR activity. The analysis of mTOR expression and 
phosphorylation in the hippocampus of Ts65Dn mice shows an aberrant activation of mTOR 
signaling starting at 6 months, which persists to 12 months of age supporting a genotype-
dependent alteration of the pathway. As a result of aberrant mTOR signaling, 
autophagosome formation is reduced in Ts65Dn mice compared with euploid mice at both 6 
and 12 months of age, suggesting its possible involvement in an increase in oxidative 
damage in Ts65Dn mice [83].
Due to the difficulties of obtaining human brain samples, only a few studies have 
investigated the role of OS in the very early ages of DS. Busciglio and Yanker, used primary 
neuronal and astrocyte cultures from fetal DS cases and normal brains and demonstrated that 
DS neurons exhibit neurodegenerative changes starting at 7 days in culture and that these 
changes are associated with increased OS levels [25].
A study of the age-depenendency of oxidative/nitrosative stress in a cohort of DS brains 
ranging from 20 to 60 years was performed by Cenini et al. in 2012 [84]. As mentioned 
previously, DS adults over the age of 40 years show neuropathological hallmarks of AD, and 
therefore this cohort was useful to highlight changes occurring in the brain before and after 
the development of AD pathology. Interestingly, among the oxidative/nitrosative stress 
markers analyzed, DS patients (<40 years) were characterized by increased total HNE levels 
together with increased levels of SDS- and FA-extracted Aβ40 and Aβ42 fractions in the 
frontal cortex [84]. A significant association was found between monomeric Aβ40 and PC 
levels [84]. This observation seems quite surprising particularly due to the well-accepted 
role of Aβ42 in promoting LPO rather than protein oxidation/nitration in AD [85]. However, 
as suggested by the same authors, one possible explanation of these data could be related to 
the amount of Aβ42 and Aβ40 measured in the frontal cortex, showing that the levels of 
Aβ40 is consistently higher than Aβ42 in the frontal cortex from DS individuals [84].
The oxidative protein modifications analysed in the frontal cortex of DS, before and after 
development of AD, and age-matched control individuals allowed identifying specific 
dysfunctional proteins. Therefore, focusing on the identification of which proteins are 
oxidatively modified in DS may provide novel insights. Proteomics analysis is a useful 
approach for this type of investigation, resulting in a better understanding of which 
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biological mechanisms are involved in the onset and progression of AD in DS, which may 
then provide useful information for clinical trials in DS.
A redox proteomics approach was used to evaluate HNE-modified proteins in the frontal 
cortex of DS and DS/AD brains along with their age-matched controls in order to shed light 
on the OS-induced altered molecular mechanisms, which characterizes DS pathology and 
my trigger the development of AD (results summarized in Table 1) [86].
By looking at the proteins identified to be HNE-modified, it appears that the majority of 
these proteins are involved in the regulation of (i) neuronal shape and trafficking; (ii) the 
proteostasis network and (iii) energy metabolism (reviewed in [67]). Intriguingly, all of these 
processes more or less rely on ATP consumption to occur efficiently. Mitochondrial 
dysfunction is an early event in the pathogenesis of neurodegenerative diseases. Reduced 
ATP levels, increased ROS, impaired calcium buffering and altered mitochondrial 
permeability are characteristic mitochondrial defects of degenerating neurons [87].
Through this analysis, Perluigi's laboratory identified increased levels of protein-bound HNE 
of myelin basic protein (MBP), α-internexin, dihydropyriminidase-related protein 1 and 2 
(DRP-1/2) in DS and DS/AD patients. This was the first report showing the oxidation of 
MBP, the major structural protein component of myelin, which plays a functional role in the 
formation and maintenance of the myelin sheath. Interestingly, it was recently demonstrated 
that MBP is able to bind Aβ and to inhibit Aβ fibril formation breakdown in white matter 
[15, 88, 89] thus suggesting a role in DS. Another member of the cytoskeleton network is α-
internexin, a 66-kDa neurofilament protein involved in the morphogenesis of neurons. 
Similarly, DRP-1 and -2 play a role in neuronal development and polarity, as well as in axon 
growth and guidance, neuronal growth cone collapse and cell migration [90]. These data 
therefore may suggest that the increased HNE modification of these proteins, whose 
expression is already altered in the fetal brain, contributes to the slow, chronic degenerative 
process of neuronal cells in DS brain [86, 90].
In addition, when oxidized/misfolded proteins accumulate in sufficient quantity, they are 
prone to form aggregates, which affect several intracellular pathways and negatively impact 
metabolism, protein turnover and trafficking [91-93]. Consistent with this hypothesis, 
SOD-1 was found to be HNE-modified in DS brain. Considering that SOD1 is 
overexpressed in DS and also oxidatively modified, it is conceivable that SOD1 aggregates 
might form and may contribute to neurotoxicity, as well as Aβ fibrils. As reported, increased 
SOD1 aggregates are present in the brain of DS/AD patients, and strengthens the hypothesis 
that impairment of SOD1 physiological activity may contribute to the development of AD 
neuropathology in DS [86].
Considering that ROS damage induces protein aggregation, which in a vicious cycle further 
leads to ROS release, the ability to remove toxic aggregates is essential to avoid 
neurodegeneration. Preserving protein homoeostasis, or ‘proteostasis’ requires several 
parallel strategies that involve refolding, degradation or clearance of misfolded polypeptides 
[94]. Any condition promoting protein misfolding load may indeed result in an alteration of 
the proteostatis network, which is a crucial aspect of cell physiology. Thus it is essential for 
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the vitality of the cell to promote a rapid and robust response to preserve/restore protein 
homoeostasis by the removal of misfolded/aggregated proteins. In particular, with regard to 
DS pathology, the maintenance of the proteostasis network could play a pivotal role not only 
for DS itself, but also for the transition to AD.
Redox proteomics analyses identified a number of HNE-modified proteins that are impaired 
in DS and DS/AD patients, which function as chaperones, or belong to the ubiquitin-
proteasome system or to the autophagy pathway. These proteins include GRP78, UCHL-1, 
HSC71 and GFAP. Therefore, alterations of these pathways predict that in degenerating 
neurons: (I) proteins with excess ubiquitinylation accumulate; (II) the activity of the 26S 
proteasome is decreased; (III) the autophagic flux is reduced and (IV) consequent 
accumulation of aggregated/damaged proteins is favoured [86].
As mentioned above, impairment of energy metabolism is also a characteristic of DS brain. 
Glucose metabolism is essential for brain health and dysfunction of glucose utilization in the 
brain represents a key component in the development of neurodegenerative disorders 
[95-97]. Furthermore, epidemiological studies show that hallmarks of metabolic disorders, 
such as glucose intolerance and/or impairment of insulin secretion, are associated with a 
higher risk of developing dementia or AD [98-101].
Analyses performed by redox proteomics revealed that fructose-bisphosphate aldolase A, C 
(FBA A/C), malate dehydrogenase, α-enolase, glycealdehyde-3-phosphate dehydrogenase, 
cytochrome b-c1 complex, aconitate hydratase and pyruvate kinase isozymes M1/M2 are 
HNE-modified in DS and DS/AD patients [86]. These enzymes that are a structural part of 
the glycolytic pathway and TCA cycle and are oxidatively modified may be toxic stressors 
within neurons by by reducing energy production.
Reduced glucose utilization due to OS-induced impairment of glycolytic enzymes would be 
further associated with increased glucose levels as occurs in the early phases of AD [102]. 
According to recently discovered mechanisms, increased glucose levels would lead to an 
increase in extracellular glutamate release, thus resulting in NMDR activation and increased 
neuronal [Ca2+], nNOS stimulation, and consequent increased OS/NS levels [103]. 
Similarly, increased glucose levels can evoke rapid changes in neuronal excitability through 
inhibition of KATP channels, which results in increased Aβ production [104]. Increased Aβ 
levels, in turn, might mediate similar effects, amplifying this vicious cycle [103] and 
promoting mitochondrial damage [30].
To note, some of the above listed proteins were found to be HNE-modified in DS (<40 
years) or DS/AD (>40 years) autopsy cases (reviewed in [67]), whereby DRP-1 and -2, 
GRP78, MPB and aconitate hydratase were also significantly different between DS and 
DS/AD groups, thus suggesting their potential role in the progression of DS toward AD 
pathology [67, 86].
5. Concluding remarks
In this review we summarized the pathophysiological role of HNE-modified proteins in DS 
neuropathology. When oxidant compounds target lipids, they can initiate the LPO process, a 
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chain reaction that produces multiple breakdown molecules, such 4-HNE. Among several 
substrates, proteins are particularly susceptible to modification caused by this highly reactive 
aldehyde. Indeed, HNE and other oxidants cause chemical modifications of proteins, mostly 
irreversible, that affect both conformational and functional integrity of target substrates and 
lead, in the majority of cases, to their dysfunction. Identification of specific HNE-modified 
proteins by redox proteomics contributed to discern which cellular function is altered in DS 
compared with healthy controls. In detail, results from our group obtained from DS brain 
suggest that LPO affects energy production, neuronal trafficking, antioxidant response and 
the efficiency of degradative systems - proteasome and autophagy. These latter pathways are 
key mechanisms of vital importance for cell survival under stress conditions and provide a 
critical protective role. If these processes are defective, then damaged/dysfunctional proteins 
are not efficiently removed and may accumulate.
These findings provided insights into the molecular mechanisms that are impaired in DS, as 
observed either from animal or human studies, and suggest that deficits of the above 
mentioned pathways are hallmarks of neurodegeneration. Indeed, impairment of energy 
metabolism and proteostasis together with reduced antioxidant defense leaves neurons more 
susceptible to the accumulation of oxidative damage that culminates in cell death. These 
defects overlap in DS and AD degenerating neurons and may suggest therapeutic targets 
valuable for both diseases.
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Figure 1. Increased lipid peroxidation product HNE leads to neurotoxic effects in Down 
syndrome brain
Trisomy of chromosome 21 in Down syndrome (DS) brain is associated with the 
overexpression of a number of proteins among which are amyloid precursor protein (APP) 
and superoxide dismutase 1 (SOD1). Overexpression of APP and SOD1 is considered to be 
associated with an increased production of amyloid beta-peptide (Aβ) and superoxide anion 
(O2-.), respectively. Furthermore, increased Aβ levels are able to promote mitochondrial 
damage and thus to sustain a further elevation of O2-. levels. These events are associated 
with an increase of both reactive oxygen species (ROS) and reactive nitrogen species (RNS), 
known to promote proteins and lipids peroxidation. Among the LPO products, 4-hydroxy-2-
nonenal (HNE) is known to bind proteins, thus modifying protein structure and promoting 
proteins impairment. Proteins found to be HNE-modified in DS brain are associated with 
reduced: (I) autophagy; (II) unfolded protein response (UPS); (III) glucose metabolism; (IV) 
antioxidant defense and (V) neuronal trafficking. All these events contribute to sustain a 
further increase of ROS/RNS, thus amplifying a vicious cycle. In addition, HNE 
modifications would promote proteins aggregation, which, because the observed defects in 
autophagy and UPS, are less cleared from neurons. Increased protein aggregation like in the 
case of Aβ and SOD1, also represent an additional stimulus sustaining ROS/RNS 
production.
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Table 1
Redox proteomics results about HNE-modified proteins in DS: overlaps with AD or MCI
Proteins DS
(Frontal Cortex)
AD
(Hippocampus, 
inferior parietal 
lobule)
MCI
(Hippocampus, 
inferior parietal 
lobule)
Function
Superoxide dismutase (Cu,Zn) ✓
Peroxiredoxin-2 ✓
Myelin basic protein ✓
Cytochrome b–c1 complex subunit Rieske, 
mitochondrial
✓
Ubiquitin carboxyl-terminal hydrolase isozyme L1 ✓
Malate dehydrogenase, cytoplasmic ✓ ✓ Energy metabolism
Glyceraldehyde-3-phosphate dehydrogenase ✓
Fructose-bisphosphate aldolase A ✓
Fructose-bisphosphate aldolase C ✓
α-Enolase ✓ ✓ ✓ Energy metabolism
Glial fibrillary acidic protein ✓
Dna J homolog subfamily B member 12 ✓
α-Internexin ✓
T-complex protein 1 subunit β ✓
Syntaxin-binding protein 1 ✓
Glutamate dehydrogenase 1, mitochondrial ✓
Pyruvate kinase isozymes M1/M2 ✓ ✓ Energy metabolism
Aconitate hydratase, mitochondrial ✓
Dihydropyrimidinase-related protein 1 ✓
Dihydropyrimidinase-related protein 2 ✓ ✓ ✓ Cell structure
Heat shock cognate 71-kDa protein ✓
78-kDa glucose-regulated protein ✓
Endoplasmin ✓
Neurofilament medium polypeptide ✓
Proteins in boldface appear in more than one group. Reference papers are: for DS group [86], for AD group [92] and for MCI group [93]
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